Remote video URL
Your peers have not rated this talk yet.
16-minute watch | Talk 6 of 7

EHA: Tracing the steps to CAR T and beyond

How should we manage our patients post CAR T?

Dr Gloria Iacoboni
Vall d’Hebron Hospital, Barcelona, Spain

Prof. Nicolaus Kröger
University Hospital Hamburg-Eppendorf, Hamburg, Germany

A patient shares insights on his post CAR T-cell therapy experience, and Dr Gloria Iacoboni, Vall d’Hebron Hospital, Barcelona, Spain, provides an overview on how to manage patients in the post CAR T-cell infusion setting, with Prof. Nicolaus Kröger, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Read more

Talks in this series

Interested in this topic?

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.